{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-276030","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.096250+00:00","generated_at":"2026-06-08T05:16:07.785078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero Q3 net loss $3.2M, revenue $25.5M on $30M GSK milestone; FDA SPA for Phase 3 tebipenem HBr","bullets":["Net loss $3.2M ($0.06/shr) vs $11.7M loss ($0.33/shr) YoY; revenue $25.5M vs $2.0M YoY driven by $23.2M GSK collaboration revenue.","Cash $93.8M expected to fund operations into H2 2025; received $30M development milestone from GSK under tebipenem HBr license.","FDA granted Special Protocol Assessment for Phase 3 PIVOT-PO trial of oral tebipenem HBr in cUTI/AP; enrollment start expected Q4 2023.","Phase 2a SPR720 trial for NTM-PD ongoing; topline data expected H2 2024. IND for SPR206 planned Q4 2023.","Sath Shukla appointed President and CEO (Aug 1); Esther Rajavelu named CFO and CBO (Nov 1), replacing prior CFO role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-276030","json":"https://secwatch.observer/filing/0001193125-23-276030.json","markdown":"https://secwatch.observer/filing/0001193125-23-276030.md","text":"https://secwatch.observer/filing/0001193125-23-276030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523276030/0001193125-23-276030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523276030/d572144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:16:07.785078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f5ded9f6a9480cb6e91ac3b77b6b13dde308009","claim":"Spero Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523276030/0001193125-23-276030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}